Neural Therapy for TIAs and Stroke Prevention Not Proven

There are no effective treatments for the recovery phase after stroke. Thus, it is imperative to explore promising treatments, especially alternative and complementary therapies, for improving recovery after ischemic stroke (Pandian 2011).

Checking your browser before accessing pmc.ncbi.nlm.nih.gov · Click here if you are not automatically redirected after 5 seconds

Repair-based therapies complement acute therapies not only in terms of different biological targets but also in terms of treatment time window, measured in days to weeks or longer, and so have the potential to help a large proportion of patients affected by stroke. Neural repair after stroke arises spontaneously after stroke and continues for many weeks, possibly for years for some behaviors particularly language and cognition.

This research may one day lead to improved prevention strategies for TIAs. The NIH StrokeNet is a centralized coordinating and data management center with 27 regional coordinating centers that are linked to more than 550 stroke hospitals across the U.S. It conducts small and large clinical trials and research studies to advance acute stroke treatment, prevention, and recovery and rehabilitation following a stroke.

In this phase 3, double-blind trial, we randomly assigned patients within 72 hours after the onset of a noncardioembolic ischemic stroke or high-risk TIA to receive asundexian (50 mg once daily) or placebo, in addition to planned dual or single antiplatelet therapy.

Studies show that patients with ischemic strokes who receive tPA are more likely to recover fully or have less disability than patients who do not receive the drug.23 Patients treated with tPA are also less likely to need long-term care in a ...

The safety of cell therapies in stroke has been demonstrated, further confirming the potential of this approach. However, efficacy of these therapies still needs to be confirmed in human subjects, and more work is needed to optimize stem cell application in clinical practice (Rust and Tackenberg, 2022). This review compiles evidence from various preclinical studies, focusing on how stem cells, especially neural stem and progenitor cells (NSCs and NPCs), contribute to brain repair after stroke, and examines the mechanisms driving stem cell-based brain regeneration.

Stem cell-based therapies have emerged as promising strategies to enhance post-stroke recovery. Building on a large body of preclinical evidence, clinical trials are currently ongoing to prove the efficacy of stem cell therapy in stroke patients. However, the mechanisms through which stem cell grafts promote neural repair remain incompletely understood.

Stem cell-based therapies have emerged as promising strategies to enhance post-stroke recovery. Building on a large body of preclinical evidence, clinical trials are currently ongoing to prove the efficacy of stem cell therapy in stroke patients. However, the mechanisms through which stem cell grafts promote neural repair remain incompletely understood.